RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncolys Biopharma - Stock

Oncolys Biopharma ROA 2024

Oncolys Biopharma ROA

-0.95

Ticker

4588.T

ISIN

JP3202170001

WKN

A1W94N

In 2024, Oncolys Biopharma's return on assets (ROA) was -0.95, a 119.19% increase from the -0.43 ROA in the previous year.

Oncolys Biopharma Aktienanalyse

What does Oncolys Biopharma do?

Oncolys Biopharma Inc. is a company specialized in the development of innovative medications for the treatment of cancer. The company was founded in 2001 in Tokyo, Japan and has become a key player in the biotechnology industry over the years. The company's business model is based on the development of innovative therapies for cancer patients. It works closely with leading scientists and researchers to advance its research projects, focusing on the discovery and development of new compounds based on the OncoTherad virus. Oncolys Biopharma Inc. offers a wide range of products and services, including cancer medications based on the OncoTherad virus, as well as diagnostic and monitoring tools for hospitals and medical facilities. It has various divisions that encompass research and development, manufacturing, and distribution and marketing of cancer medications and diagnostic systems. The company is committed to expanding its research and development activities to develop new medications for different types of cancer. In addition to cancer medications, Oncolys Biopharma Inc. is also working on developing therapies for other serious illnesses such as viral diseases. The company has a promising pipeline of new medications being tested in various clinical trials. Overall, Oncolys Biopharma Inc. is a key player in the biotechnology industry specializing in the development of innovative therapies for cancer and viral diseases. The company has built an excellent reputation over the years and is committed to continuing its growth and expansion. Oncolys Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Oncolys Biopharma's Return on Assets (ROA)

Oncolys Biopharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Oncolys Biopharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Oncolys Biopharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Oncolys Biopharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Oncolys Biopharma Stock

What is the Return on Assets (ROA) of Oncolys Biopharma this year?

The Return on Assets (ROA) of Oncolys Biopharma is -0.95 undefined this year.

What was the ROA of Oncolys Biopharma compared to the previous year?

The ROA of Oncolys Biopharma has increased by 119.19% compared to the previous year.

What consequences do high ROA have for investors of Oncolys Biopharma?

A high ROA is advantageous for investors of Oncolys Biopharma, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Oncolys Biopharma?

A low ROA can be unfavorable for investors of Oncolys Biopharma as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Oncolys Biopharma affect the company?

An increase in ROA of Oncolys Biopharma can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Oncolys Biopharma impact the company?

A reduction in the ROA of Oncolys Biopharma can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Oncolys Biopharma?

Some factors that can influence the ROA of Oncolys Biopharma include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Oncolys Biopharma important for investors?

The ROA of Oncolys Biopharma is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Oncolys Biopharma take to improve ROA?

To improve ROA, Oncolys Biopharma can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Oncolys Biopharma pay?

Over the past 12 months, Oncolys Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncolys Biopharma is expected to pay a dividend of 0 JPY.

What is the dividend yield of Oncolys Biopharma?

The current dividend yield of Oncolys Biopharma is .

When does Oncolys Biopharma pay dividends?

Oncolys Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncolys Biopharma?

Oncolys Biopharma paid dividends every year for the past 0 years.

What is the dividend of Oncolys Biopharma?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncolys Biopharma located?

Oncolys Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncolys Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncolys Biopharma from 6/28/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Oncolys Biopharma pay the last dividend?

The last dividend was paid out on 6/28/2024.

What was the dividend of Oncolys Biopharma in the year 2023?

In the year 2023, Oncolys Biopharma distributed 0 JPY as dividends.

In which currency does Oncolys Biopharma pay out the dividend?

The dividends of Oncolys Biopharma are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncolys Biopharma

Our stock analysis for Oncolys Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncolys Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.